Ultrasound-driven for Sonodynamic Therapy of Hepatocellular Carcinoma

Abstract

Hepatocellular carcinoma (HCC) is characterized by high malignancy, high recurrence rate and poor prognosis. Existing treatment still face challenges such as insufficient precision, limited efficacy, and significant side effects, and there is an urgent need for developing novel therapies. Sonodynamic therapy (SDT) has emerged as a promising alternative to conventional cancer therapies, by using ultrasound-deriven to activate sonosensitizers and generate reactive oxygen species (ROS). This review aims to establish a foundation and guide future investigations toward the clinical application of SDT in hepatocellular carcinoma management.

Article information

Article type
Review Article
Submitted
26 Jan 2026
Accepted
13 Feb 2026
First published
13 Feb 2026

Chem. Commun., 2026, Accepted Manuscript

Ultrasound-driven for Sonodynamic Therapy of Hepatocellular Carcinoma

W. Chen, L. Dong and X. Xiao, Chem. Commun., 2026, Accepted Manuscript , DOI: 10.1039/D6CC00520A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements